Page 38 - Dan Budwick News Today : Breaking News, Live Updates & Top Stories | Vimarsana

(2) Merger of 10 Privately Held Biotech Companies with Highly Validated Programs Led by Industry Leading Teams to Operate Under Centessa Umbrella Company Founded by Medicxi with Financing Led by General Atlantic, and Co-led by Vida Ventures and Janus Henderson Investors Saurabh Saha, M.D., Ph.D., Former Senior Vice President, R&D, and Global Head of Translational Medicine at Bristol Myers Squibb, Appointed as Chief Executive Officer Moncef Slaoui, Ph.D., Former Chief Scientific Advisor of Operation Warp Speed, Former Chairman of R&D at GlaxoSmithKline, Partner at Medicxi, Appointed as Chief S...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Rubius Therapeutics to Participate in Guggenheim Healthcare Talks | 2021 Oncology Days Rubius TherapeuticsFebruary 3, 2021 GMT CAMBRIDGE, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, and the executive man...

Press release content from Business Wire. The AP news staff was not involved in its creation. MOMA Therapeutics Appoints Asit Parikh, M.D., Ph.D. as President and Chief Executive Officer February 1, 2021 GMT CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 1, 2021-- MOMA Therapeutics, a biopharmaceutical company discovering the next generation of precision medicines by targeting molecular machines that underlie human disease, today announced that Asit Parikh, M.D., Ph.D., has been appointed as the company’s president and chief executive officer, effective April 5, 2021. Dr. Parikh brings more than 20...

Press release content from Business Wire. The AP news staff was not involved in its creation. Gilead Sciences and Gritstone Announce Collaboration Utilizing Gritstone’s Vaccine Platform Technology for HIV Cure February 1, 2021 GMT FOSTER CITY, Calif. & EMERYVILLE, Calif.--(BUSINESS WIRE)--Feb 1, 2021-- Gilead Sciences, Inc. (Nasdaq: GILD) and Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today announced that the companies have entered into a collaboration, option and license agreement...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Gritstone and Genevant Sciences Announce License Agreement for COVID-19 Vaccine Gritstone Oncology, IncJanuary 20, 2021 GMT — Deal provides nonexclusive access to Genevant’s leading LNP technology for use in Gritstone’s self-amplifying RNA COVID-19 vaccine program; NIH-sponsored Phase 1 clinical trial expected to initiate in 1Q21 — — Agreement is the second between the parties since October 2020 — EMERYVILLE, Calif. and VANCOUVER, British Columbia and BASEL, Switzerland , Jan. 20, 2021 ...